Home › Vascular Diseases › Ohio › Cleveland
Vascular Diseases clinical trials in Cleveland, OH
4 studies for Vascular Diseases are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
Recruiting
- Cleveland Clinic, Cleveland
Zenith® Fenestrated+ Clinical Study
Recruiting
- Cleveland Clinic Foundation, Cleveland
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
RecruitingObservational study
- University Hospitals - Cleveland Medical Center, Cleveland
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
Recruiting
- Cleveland Clinic, Cleveland
About Vascular Diseases
Your vascular system is made up of blood vessels that carry blood to and from the heart. Learn about vascular diseases and their treatments.
More about Vascular Diseases on MedlinePlus
Vascular Diseases trials in other cities
- Boston, MA13 studies
- Washington, DC7 studies
- St. Louis, MO5 studies
- Durham, NC5 studies
- Dallas, TX5 studies
- Atlanta, GA4 studies
- Mountain View, CA4 studies
- Los Angeles, CA4 studies
- Tampa, FL4 studies
- Detroit, MI4 studies
- New York City, NY4 studies
- Rochester, MN3 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)36 studies
- Breast Cancer33 studies
- Heart Failure31 studies
- Metastatic Cancer30 studies
- Prostate Cancer30 studies
- Ovarian Cancer29 studies
- Lung Cancer26 studies
- Colorectal Cancer25 studies
- Acute Myeloid Leukemia20 studies
- Head and Neck Squamous Cell Carcinoma20 studies
- Cardiovascular Disease20 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.